Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief Commercial and Strategy Officer, talks with Paul Bridges, Worldwide Head of Regulatory and Access, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism
Most Recent Articles
Episode 12: ASCO20 Debrief: The latest in cell and gene therapy
In 2020, ASCO went virtual for the first time. While the format was different, one thing was clear: despite all that is happening in the world, there are still many patients in need. Todd Shuster,...
Episode 11: Maintaining Clinical Trial Continuity During COVID-19: The Patient Perspective
Now more than ever it's important to recognize and show our appreciation for clinical trials and the critical role that they play in advancing public health. Since the outbreak of the COVID-19...
Episode 10: The emerging role of wearables in clinical trials
The COVID-19 pandemic has forced us to rethink just about every aspect of clinical trials. An area of significant potential is the use of wearables as part of Decentralized Clinical Trials (DCTs)....
Episode 9: Making the Most of Functional Service Provider (FSP) Relationships
In this episode, we discuss how Functional Service Provider or FSP partnerships have been gaining traction and increasing in relevance in today’s environment because of their potential to offer...
Episode 8: Performing clinical trials in a shifting development landscape
The COVID-19 pandemic is having lasting and far-reaching impact on the drug development industry. Fundamental aspects of drug development are undergoing changes that were unimaginable just weeks...
Episode 7: International Women’s Day: Insights from Ascending Davos
In this episode, Parexel Executive Vice President and Chief Commercial & Strategy Officer Peyton Howell interviews Meghan FitzGerald, Parexel Board Advisor and author of the new book Ascending...
Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients
Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how biotech companies can incorporate precision medicine into their development plans.
Episode 5: CAR-T: How far have we come and where are we going?
In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s...
Episode 4: Accelerated Regulatory Pathways and Patient Access
In this episode, Parexel’s Mwango Kashoki, a former FDA regulator, and Richard Macaulay, who specializes in market access challenges, join Alberto Grignolo to discuss expedited regulatory pathways...
Episode 3: Bridging the Gap – How Minimizing Patient Barriers Can Improve Clinical Research
In this episode Alberto Grignolo, Corporate Vice President, Parexel, Sy Pretorius, Executive Vice President and Chief Medical and Scientific Officer, Parexel, and Roz Round, Director of Parexel's...
Episode 2: Tackling Rare Diseases & Inside the FDA
Recorded during the 2019 World Orphan Drug Congress, this episode brings together Amy McKee and Mo Heidaran who both recently joined PAREXEL from the FDA, as well as Zizi Imatorbhebhe, an expert...
Episode 1: International Women's Day
In our inaugural podcast, Siri Chilazi, a gender equality expert and Harvard Kennedy School Research Fellow, speaks with female leaders from PAREXEL - Dr. Kemi Olugemo, Dr. Ubavka DeNoble, Aida...